Stay updated on Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial page
- Check5 days agoChange DetectedThe page now includes Melanoma as a topic and related topics such as MedlinePlus Genetics, and the revision tag has been updated from v3.6.5 to v3.6.6. This updates contextual metadata and navigation references without altering the study data or outcomes.SummaryDifference0.2%

- Check12 days agoChange DetectedAn NIH funding annotation, “2016 ( U.S. NIH Grant/Contract ),” was added to the study's identifying numbers. This connects the grant/contract information with the existing identifiers for the trial.SummaryDifference0.1%

- Check19 days agoChange DetectedThe study's condition label Melanoma and related resources (related topics: and MedlinePlus Genetics) have been removed from the page. This indicates a restructuring of the study’s condition labeling and its related-resource references.SummaryDifference0.2%

- Check26 days agoChange DetectedA new Revision: v3.6.5 label was added to the page, indicating an update. The Investigator Inquiry Form was removed, and the previous Revision: v3.6.4 entry was deleted.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, reflecting a new page/software release. The change denotes an updated version of the page/template rather than changes to user-facing content.SummaryDifference0.0%

- Check62 days agoChange DetectedFooter revision label updated from v3.6.2 to v3.6.3. This is a minor documentation update and does not change any study details or page content.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial page.